Last updated on March 2019

Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

Brief description of study

A Phase 2, multicenter, double-blind, placebo control study evaluating the safety and efficacy of Thykamine in adult patient suffering of mild-to-moderate Atopic Dermatitis

Detailed Study Description

4-week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of Three Concentrations (0.05%, 0.1% and 0.25%) of PUR 0110 (Thykamine) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis.

Clinical Study Identifier: NCT03540043

Find a site near you

Start Over